MedTrace Logo

The FEIBA NovoSeven Comparative Study

NCT00166309 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-04-19

No results posted yet for this study

Summary

FENOC is a prospective, open-label, randomized, cross-over, multi-center study to investigate and compare the hemostatic effect and cost-efficacy of two different by-passing agents in the treatment of joint hemorrhages in subjects with severe hemophilia A and inhibitors. The study is designed as a clinical equivalency trial.

Conditions

  • Severe Hemophilia A With an Inhibitor

Interventions

DRUG

FEIBA and NovoSeven

Sponsors & Collaborators

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Erik Berntorp, MD, PhD · Skane University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
2 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Completion
2005-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00166309 on ClinicalTrials.gov